Stockscreener 앱 받기
3.57
1.13%
0.04
시간 외 거래:
3.59
0.02
+0.56%
Briacell Therapeutics Corp 주식(BCTX)의 최신 뉴스
(BCT) Strategic Equity Report (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics Corp (BCTXW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Briacell Therapeutics Corp (BCTX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Enterprise value to revenue forward of BriaCell Therapeutics Corp. – NASDAQ:BCTXZ - tradingview.com
Briacell Therapeutics Corp (BCTX) Peer Comparison – Compare with Others - Value Research
Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. - marketscreener.com
BriaCell's Cell-Based ‘Melanoma’ Enters the Skin Cancer Vaccine Conversation - Investing News Network
BriaCell Therapeutics Stock Faces Renewed Pressure as Biotech Volatility Tests Investor Conviction - kalkine.ca
BriaCell Therapeutics Corp. (TSX:BCT) Falls 4.24% as Clinical-Stage Risk and Volatility Pressure Sentiment - kalkine.ca
BriaCell Therapeutics Corp (BCTXW) Peer Comparison – Compare with Others - Value Research
Briacell Therapeutics Corp (BCTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
BriaCell Therapeutics Stock Falls Sharply: Can TSX:BCT Stabilize After Renewed Biotech Selling Pressure? - kalkine.ca
BriaCell Therapeutics Stock Falls 6.41%: Why TSX:BCT Is in Focus as Breast and Prostate Cancer Pipeline Advances - kalkine.ca
BriaCell Therapeutics Corp. (TSX:BCT) Gains Momentum as Immunotherapy Pipeline Progress Supports Investor Optimism - kalkine.ca
BriaCell Therapeutics (TSX:BCT) Advances 6.6% on a Run of Pipeline Milestones - kalkine.ca
BriaCell in Focus: TSX: BCT Investors Watch Major Immunotherapy Milestones Ahead of Clinical Data - kalkine.ca
BriaCell Therapeutics Stock Slides 13.31%: Can Clinical Execution Overcome Renewed Biotech Pressure? - kalkine.ca
BriaCell stock choppy on melanoma vaccine milestone - Investing.com
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™ - Yahoo Finance
BCTX Stock Pulls Back As Traders Gauge Biotech Risk - timothysykes.com
BriaCell (BCTXZ) Session: Advances 2.54% to $0.10 in Latest Trading; Next Test: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingShort Term Trading Ideas - vinanet.vn
BriaCell (BCTXL) Stock: Trades in a Narrow Directional Range at $1.00 in Latest Trading; Chart Watch: the Price Remains Bounded by the Supplied Support and Resistance under the Current SnapshotFibonacci Fan - vinanet.vn
Why Did BriaCell Therapeutics (TSX:BCT) Surge 12.37% on 19 August 2026? - kalkine.ca
BriaCell (BCTX) Results Breakdown: Reported EPS Tops Expectations in the Current Update; After Earnings - vinanet.vn
BriaCell Therapeutics Stock Rises 3.19% as Phase 3 Breast Cancer Trial and Bria-IMT Progress Draw Investor Interest - kalkine.ca
BriaCell Therapeutics Stock: A Breast-Cancer Immunotherapy Nears Late-Stage Data - kalkine.ca
BCTX Q2 2026 Earnings: Narrower-Than-Expected Loss of -$2.58 Beats Estimates by 47.22%Revenue Recognition Risk - Vinanet
Briacell Therapeutics Corp (BCTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BCTXL Holds Steady at $0.85 as BriaCell Warrant Trades in Tight RangeVolume Nodes - Vinanet
BriaCell Therapeutics Corp (TSX:BCT) Shares Decline as Biotech Uncertainty, Funding Risks and Clinical Execution Concerns Pressure Sentiment - kalkine.ca
Enterprise value to EBIT forward of BriaCell Therapeutics Corp. – BOATS:BCTXL - TradingView
BriaCell Therapeutics Corp. (BCTXZ) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Briacell Therapeutics Corp (BCTX) Stock News Today - TradingKey
BCTX Q2 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline AdvancesRevenue Growth Outlook - vinanet.vn
BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer - Investing News Network
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer - The Manila Times
FDA clearance lets BriaCell test personalized prostate immunotherapy - Stock Titan
BriaCell Therapeutics (BCTX) Rises 3.86% to $3.5 as Immuno-Oncology Interest BuildsVolatility Stop - vinanet.vn
Why Did BriaCell Therapeutics Corp. (TSX:BCT) Stock Fall 5.49% on 31 July 2026? - kalkine.ca
BriaCell Therapeutics (BCTX) Slides 5.2% to $3.44 as Biotech Selling Pressure IntensifiesOBV Breakout - siam.in
BriaCell Therapeutics Warrant (BCTXZ) Holds at $0.09 as Long-Dated Biotech Option Trades FlatUp Down Volume - dars.gov.et
BriaCell Therapeutics Corp Revenue Breakdown – TSX:BCT - tradingview.com
BriaCell Therapeutics Corp. Revenue Breakdown – BOATS:BCTXL - TradingView
Briacell Therapeutics Corp (BCTX) Institutional Confidence - TradingKey
Briacell Therapeutics Corp (BCTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BCTX|Briacell Therapeutics Corp|Price:3.338|Chg%:-0.022 - TradingKey
BCTXL Slips 7.87%: Support Test for BriaCell WarrantModified Schiff - vinanet.vn
Briacell Therapeutics Corp (BCTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Briacell Therapeutics Corp (BCTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Briacell Therapeutics Corp (BCTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BriaCell Therapeutics Market Sentiment - Benzinga España
Briacell Therapeutics Corp (BCTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Briacell Therapeutics Corp (BCTX) Income Statement - TradingKey
BCTX|Briacell Therapeutics Corp|Price:3.525|Chg%:-0.055 - TradingKey
Briacell Therapeutics Corp (BCTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BCTX Q2 2026 Earnings: Narrower-than-expected loss as clinical-stage biotech advances pipelineEarnings Preview - Vinanet
TradingKey - TradingKey
BriaCell Therapeutics Corp. Revenue Breakdown – NASDAQ:BCTXL - TradingView
BriaCell Therapeutics Corp. Revenue Breakdown – NASDAQ:BCTXZ - TradingView
BCTX Q2 2026 Earnings: Narrower Loss Beats Estimates Amid Drug Development ProgressEarnings Season Outlook - vinanet.vn
BriaCell Therapeutics Corp Revenue Breakdown – MUN:8BT - TradingView
BCTX|Briacell Therapeutics Corp|Price:3.580|Chg%:-0.140 - TradingKey
BriaCell Therapeutics Warrant (BCTXL) Holds Steady at $0.89 as Support and Resistance Levels Come into FocusHidden Order - dars.gov.et
Price to earnings forward of BriaCell Therapeutics Corp. – NASDAQ:BCTXZ - TradingView
Why Briacell Therapeutics Corp stock is sliding today - Wealth Awesome
BriaCell Therapeutics Stock Slips as Biotech Risk Appetite Weakens: Is TSX:BCT Facing Near-Term Pressure? - kalkine.ca
What's Going On With Briacell Therapeutics Corp Stock Monday? - Wealth Awesome
BriaCell Therapeutics Warrants (BCTXZ) Spike 9.32% as Shares Test Key Support at $0.10Fast Moving Stocks - vinanet.vn
Is CRA International’s New Bria-IMT Role Quietly Redefining Its Healthcare Moat and Pricing Power (CRAI)? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
0.86%
0.31%
자본화:
|
볼륨(24시간):